Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19698948 | 0.88 | NR1H4 (0.45) | NR1H4GABRB3GABRA2GABRB2OPRL1 | |
| SCHEMBL19689518 | 0.88 | NR1H4 (0.47) | NR1H4GABRB3GABRA2GABRB2OPRL1 | |
| SCHEMBL17839932 | 0.83 | NR1H4 (0.41) | NR1H4MAPK14 | |
| SCHEMBL20833797 | 0.82 | NR1H4 (0.40) | NR1H4OPRL1MAPK14 | |
| SCHEMBL20833739 | 0.80 | NR1H4 (0.42) | NR1H4OPRL1MAPK14 | |
| SCHEMBL20833799 | 0.75 | NR1H4 (0.36) | NR1H4OPRL1 | |
| SCHEMBL30807047 | 0.75 | NR1H4 (0.36) | NR1H4OPRL1 | |
| SCHEMBL20833979 | 0.73 | TP53 (0.36) | — | |
| SCHEMBL19689539 | 0.72 | NR1H4 (0.39) | NR1H4GABRB3GABRA2GABRB2 | |
| SCHEMBL1097296 | 0.70 | NR1H4 (0.40) | NR1H4MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4534536-A1 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| CN-117924266-A | Compounds that modulate FXR (NR 1H 4) | 吉利德科学公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-117924267-A | Compounds that modulate FXR (NR 1H 4) | 吉利德科学公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-109476636-B | Compounds that modulate FXR (NR 1H 4) | 吉利德科学公司 | 2024-01-09 | — | — | CN | disclosed |
| US-11739065-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739065-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739065-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| EP-4089072-A1 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| US-20220204460-A1 | FXR (NR1H4) MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2022-06-30 | — | — | US | disclosed |
| US-20220204460-A1 | FXR (NR1H4) MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2022-06-30 | — | — | US | disclosed |
| US-10421730-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2019-09-24 | — | — | US | disclosed |
| EP-3257847-B1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2019-08-21 | — | — | EP | disclosed |
| EP-3257847-B1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2019-08-21 | — | — | EP | disclosed |
| WO-2017218330-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2017-12-21 | — | — | WO | disclosed |
| WO-2017218330-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2017-12-21 | — | — | WO | disclosed |
| EP-3257847-A1 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2017-12-20 | — | — | EP | disclosed |
| EP-3257847-A1 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739065-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885GABRB3 253/4885GABRA2 547/4885 |
| US-10421730-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885GABRB3 253/4885GABRA2 547/4885 |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885GABRB3 253/4885GABRA2 547/4885 |
| US-20220204460-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885GABRB3 253/4885GABRA2 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.